Your Health, We Care
Release date: 2024-08-14 10:52:22 Recommended: 135
Pemigatinib leads to constitutive activation of FGFR by activating FGFR amplification and fusion, thereby inhibiting FGFR1-3 phosphorylation and signaling and decreasing cell viability.
In a phase II clinical trial called FIGHT-202, Pemigatinib was evaluated in 107 patients with locally advanced or metastatic cholangiocarcinoma who had previously undergone FGFR2 gene fusion or nonfusion reconstruction. The results showed that among patients treated with Pemigatinib, the objective response rate (ORR) reached 36%, with 2.8% achieving complete response and 33% achieving partial response. In addition, 63% of patients achieved remission at 6 months or more, and 18% maintained remission at 12 months or more.
Clinical studies have shown that the median overall survival (OS) of Pemigatinib is 21.1 months, which is more than 3-fold compared to the historical average survival of patients treated with second and third-line therapy in the past, which is 6-7 months.
Pemigatinib inhibits the growth and spread of tumor cells by inhibiting the phosphorylation and signaling processes of FGFR1-3 and blocking the constitutive activation of FGFR signaling caused by FGFR amplification and fusion. In clinical trials, patients treated with Pemigatinib showed a reduction in tumor volume.
Pemigatinib has a high disease control rate (DCR) of 82%, indicating that the drug has a significant effect in controlling disease progression.
Pemigatinib can significantly prolong the overall survival of patients and bring new hope for the treatment of cholangiocarcinoma patients.
Pemigatinib is the first FDA-approved targeted therapy for cholangiocarcinoma, bringing a new breakthrough in the treatment of cholangiocarcinoma. In the future, with further research on Pemigatinib and the accumulation of clinical application experience, the drug is expected to play a greater role in the treatment of cholangiocarcinoma.
In addition, Pemigatinib has also been in clinical trials in other types of tumors, such as bladder cancer, urothelial cancer, colorectal cancer, and myeloproliferative tumors, showing broad application prospects.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
